FDA Approves Lantheus Brain-Imaging Agent
Quick Facts
How Can the New Brain-Imaging Agent Help Assess Alzheimer’s Disease?
Molecular imaging uses a small amount of a radioactive tracer to reveal biological changes that conventional structural scans may not show. The newly approved Lantheus agent gives specialists another way to investigate Alzheimer’s-related changes in appropriate patients, although its precise clinical use and interpretation must follow the FDA-approved label.
Such imaging can strengthen or weaken a suspected diagnosis when a person has cognitive symptoms but the cause remains uncertain. It is not a stand-alone dementia test: clinicians must consider the scan together with cognitive assessments, neurological examination, medication effects, laboratory findings and structural imaging.
Does a Positive Brain Scan Confirm Alzheimer’s Disease?
Biomarker abnormalities can occur before noticeable memory problems, and some may be present in people whose symptoms arise from another condition. Conversely, a negative result only addresses the specific biological target and clinical setting covered by the tracer’s approved indication.
Specialist interpretation is therefore essential. Updated Alzheimer’s diagnostic frameworks increasingly incorporate biomarkers, but they also emphasize that test results should be connected to the patient’s clinical presentation rather than treated as an isolated diagnosis.
Who Might Be Referred for Alzheimer’s Molecular Imaging?
Appropriate-use recommendations have historically focused on patients with objectively confirmed cognitive problems whose diagnosis remains uncertain after a thorough evaluation. Routine screening of people without symptoms is not generally recommended outside research or another clearly defined clinical pathway.
Before ordering imaging, clinicians should discuss what the possible results mean, whether they would change management and the limitations of the test. Patients should also receive information about radiation exposure, preparation requirements, insurance coverage and access to facilities equipped to perform and interpret molecular brain imaging.
Frequently Asked Questions
No. It is a diagnostic imaging agent used to support assessment; it does not remove disease-related proteins, restore memory or slow Alzheimer’s progression.
No. Cognitive testing, medical history, neurological examination and evaluation for other reversible or treatable causes remain important parts of diagnosis.
Routine biomarker imaging of people without cognitive symptoms is not generally recommended. Testing should be considered with a qualified clinician when the result is likely to answer a defined medical question.
References
- Reuters. US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment. August 17, 2026.
- Alzheimer’s Association. Revised Criteria for Diagnosis and Staging of Alzheimer’s Disease. Alzheimer’s & Dementia. 2024.
- Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate Use Criteria for Amyloid PET. Alzheimer’s & Dementia. 2013.